ArticleJHEP reports : innovation in hepatology2023

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.

Richard J Thompson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.